Application | Comment | Organism |
---|---|---|
drug development | design of epitope-based vaccines, where epitopes preferably should be those in which the virus is unable to mutate due to viral fitness | Hepacivirus C |
Protein Variants | Comment | Organism |
---|---|---|
additional information | sequentially mutated 180 protease-domain residues to Ala or Gly in a functional full-length NS3/4A gene. Most (87%) protease residues can be replaced and protease activity is retained, suggesting that the protease has an unexpectedly high plasticity | Hepacivirus C |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
additional information | human leukocyte antigen A2restricted epitope in which substitutions at 5 of 9 residues destroy the protease | Hepacivirus C |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Hepacivirus C | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|
Synonyms | Comment | Organism |
---|---|---|
nonstructural 3 protease | - |
Hepacivirus C |
NS3 protease | - |
Hepacivirus C |
NS3/4A protease | - |
Hepacivirus C |